Core Viewpoint - Changjiang Life Science Technology (00775) has seen a significant stock increase of over 8%, currently trading at 1.01 HKD, with a transaction volume of 23.28 million HKD, following the presentation of its tumor growth inhibition research results at the SITC 2025 conference [1] Group 1: Company Developments - The company showcased major advancements in cancer vaccines targeting TROP2, PRAME, and PD-L1 at the SITC 2025 conference [1] - Dr. Du Jianming, Vice President and Chief Scientific Officer of the company, expressed optimism about the results of the cancer vaccine candidates targeting TROP2 and PRAME/PD-L1, indicating a potential acceleration in the development of effective therapeutic cancer vaccines [1] - The current goal for the company is to advance these vaccine candidates to the clinical trial stage [1]

Core Viewpoint - The financial market connectivity in the Guangdong-Hong Kong-Macao Greater Bay Area is continuously deepening, driven by reforms and opening up, enhancing international competitiveness and collaboration among financial institutions [1][2][3]. Financial Market Connectivity - As of September 2025, the cumulative transaction amount of the "Shenzhen-Hong Kong Stock Connect" is 125 trillion yuan, with the Shenzhen Stock Connect becoming the main channel for foreign investment in A-shares, while the Hong Kong Stock Connect injects liquidity into the Hong Kong market [2]. - The "Cross-Border Wealth Management Connect" has expanded, with a scale exceeding 120 billion yuan, and has seen a significant increase in participation from individual investors [9]. Internationalization of Financial Institutions - Domestic and foreign banks are increasingly engaging in mutual cooperation, exemplified by WeBank's establishment of WeBank Technology in Hong Kong, which has expanded its reach to multiple markets and engaged over 20 partners with intentions exceeding hundreds of millions of dollars [5][6]. - Global financial institutions are intensifying their presence in the Greater Bay Area, with HSBC and Fubon Bank establishing new offices and Santander Bank receiving approval for its Shenzhen branch [6][7]. Securities Industry Developments - The "Cross-Border Wealth Management Connect" 2.0 has seen over 160,000 individual investors participating, marking a growth of over 120% compared to version 1.0 [9][10]. - Securities firms are optimistic about the upcoming "Cross-Border Wealth Management Connect" 3.0, which is expected to expand beyond the Greater Bay Area to major cities like Beijing and Shanghai [10]. - Guangdong-based securities firms are increasing their investments in Hong Kong subsidiaries to build a second growth curve, with notable investments from firms like GF Securities and First Capital Securities [10][12]. Cross-Border Insurance Services - The cross-border insurance services are improving, with policies supporting the development of cross-border medical insurance and vehicle insurance [14][15]. - As of mid-2023, cross-border vehicle insurance has provided coverage for 90,300 vehicles, and health insurance has served over 150,000 individuals [14][15]. - Insurance institutions are establishing operations in the Greater Bay Area to enhance international business, with companies like PICC Hong Kong and China Taiping actively participating in regional development [16]. Upcoming Events - The 20th China Economic Forum will take place on November 18 in Nansha, focusing on the integration of technology and finance, with over 200 representatives from government, listed companies, and financial institutions expected to attend [20].

Group 1 - The stock of Changjiang Life Science Technology (00775.HK) rose nearly 7% in the afternoon trading session, with a current increase of 6.82% [1] - The stock price is reported at 0.94 HKD, with a trading volume of 10.4298 million HKD [1]

Core Viewpoint - 长江生命科技 has demonstrated significant advancements in cancer immunotherapy, particularly in the development of innovative vaccines targeting specific cancer antigens, which has positively impacted its stock performance [1] Group 1: Stock Performance - Long江生命科技's stock rose nearly 7%, with a current increase of 6.82%, trading at 0.94 HKD, with a transaction volume of 10.43 million HKD [1] Group 2: Research and Development Achievements - The company showcased its research findings at the SITC 2025 conference, focusing on the development of cancer vaccines targeting TROP2, PRAME, and PD-L1, highlighting their potential to inhibit tumor growth [1] - Two innovative vaccines targeting TROP2 protein were disclosed, which is highly expressed in various cancers, including breast cancer, lung cancer, and colorectal cancer [1] - The company also announced the development of a vaccine that simultaneously targets PD-L1 and PRAME, with significant T-cell activation effects [1] - In a preventive lung cancer model, the vaccine demonstrated a tumor growth inhibition rate exceeding 95%, maintaining defensive capabilities even three months post-vaccination, indicating the potential for long-lasting immune memory [1]

Core Viewpoint - Changjiang Life Science (00775) experienced a nearly 7% increase in stock price, reaching 0.94 HKD, following the presentation of significant advancements in cancer immunotherapy at the SITC 2025 conference [1] Group 1: Company Developments - Changjiang Life Science showcased research results on tumor growth inhibition at the SITC 2025 conference, focusing on innovative cancer vaccines targeting TROP2, PRAME, and PD-L1 [1] - The company revealed two innovative vaccines targeting the TROP2 protein, which is highly expressed in various cancers including breast cancer, lung cancer, and colorectal cancer [1] - Additionally, the company announced the development of a vaccine that simultaneously targets PD-L1 and PRAME, with notable T-cell activation effects [1] Group 2: Research Outcomes - In a preventive lung cancer model, the vaccine demonstrated a tumor growth inhibition rate exceeding 95% after administration [1] - The vaccine maintained its defensive capability against tumor re-challenge tests three months post-vaccination, indicating the potential for inducing long-lasting immune memory [1]

Core Viewpoint - Changjiang Life Science Technology (00775) experienced a nearly 7% increase in stock price, attributed to the presentation of significant advancements in cancer immunotherapy at the SITC 2025 conference [1] Group 1: Company Developments - The company showcased research results on tumor growth inhibition, focusing on innovative cancer vaccines targeting TROP2, PRAME, and PD-L1 [1] - Two innovative vaccines targeting the TROP2 protein were disclosed, which is highly expressed in various cancers including breast, lung, and colorectal cancers [1] - The company also announced the development of a vaccine that simultaneously targets PD-L1 and PRAME, with notable T-cell activation effects [1] Group 2: Research Outcomes - In a preventive lung cancer model, the vaccine demonstrated a tumor growth inhibition rate exceeding 95% after administration [1] - The vaccine maintained its defensive capability against tumor re-challenge tests three months post-administration, indicating the potential for long-lasting immune memory [1]

致：香港交易及結算所有限公司 公司名稱: 長江生命科技集團有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00775 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 15,000,000,000 | HKD | | 0.1 HKD | | 1,500,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 15,000,000,000 | HKD | | 0.1 HKD | | 1,500,000,000 | 本月底法定/註冊股本 ...

（於開曼群島註冊成立之有限公司） （股份代號：0775） 執行董事 董事名單與其角色及職能 長江生命科技集團有限公司董事會（「董事會」）成員載列如下。 附註： * 亦包括其他集團要員 C 有關董事會轄下委員會之主席 M 有關董事會轄下委員會之委員 香港，二零二五年十一月一日 | Peter Peace Tulloch | （非執行董事） | | --- | --- | | 郭李綺華 | （獨立非執行董事） | | 關啟昌 | （獨立非執行董事） | | Paul Joseph Tighe | （獨立非執行董事） | | 羅弼士 | （獨立非執行董事） | 董事會設立5個董事會轄下委員會。下表提供董事會成員在該等轄下委員會中所 擔任之角色。 | 董事會轄下委員會 | | | 審核委員會 薪酬委員會 提名委員會 可持續發展 | | 執行委員會* | | --- | --- | --- | --- | --- | --- | | 董事 | | | | 委員會* | | | 李澤鉅 | | M | M | | C | | 甘慶林 | | | | | M | | 葉德銓 | | | | M | M | | 余英才 | ...

Summary of Key Points Core Viewpoint - The report highlights the top short-selling stocks in the market, indicating significant investor sentiment and potential volatility in these companies' stock prices [1]. Group 1: Top Short-Selling Ratios - JD Health-R (86618) has the highest short-selling ratio at 100.00% [2] - China Resources Beer-R (80291) follows with a short-selling ratio of 97.44% [2] - Sun Hung Kai Properties-R (80016) ranks third with a short-selling ratio of 77.85% [2] Group 2: Top Short-Selling Amounts - Alibaba-SW (09988) leads in short-selling amount with 3.449 billion [2] - Tencent Holdings (00700) has a short-selling amount of 3.116 billion [2] - Meituan-W (03690) follows with a short-selling amount of 2.066 billion [2] Group 3: Top Short-Selling Deviation Values - Dream Garden (N23076) has the highest deviation value at 33.73% [2] - Changjiang Life Technology (00775) follows with a deviation value of 32.22% [2] - Geely Automobile-R (80175) ranks third with a deviation value of 30.81% [2]

Core Insights - The article highlights the top short-selling stocks in the market, with Anta Sports-R and Great Wall Motors-R both having a short-selling ratio of 100.00% [1][2] - Alibaba-SW leads in short-selling amount at 1.343 billion, followed by Pop Mart at 1.242 billion and Tencent Holdings at 1.215 billion [1][2] Short-Selling Ratios - Anta Sports-R (82020) has a short-selling amount of 635,500 and a ratio of 100.00% with a deviation of 10.36% [2] - Great Wall Motors-R (82333) has a short-selling amount of 7,250 and a ratio of 100.00% with a deviation of 30.20% [2] - SenseTime-WR (80020) has a short-selling amount of 1,122,200 and a ratio of 97.63% with a deviation of 51.92% [2] - Lenovo Group-R (80992) has a short-selling amount of 2,438,200 and a ratio of 94.23% with a deviation of 34.69% [2] Short-Selling Amounts - Alibaba-SW (09988) has a short-selling amount of 1.343 billion with a ratio of 9.98% and a deviation of -6.17% [2] - Pop Mart (09992) has a short-selling amount of 1.242 billion with a ratio of 30.78% and a deviation of 9.42% [2] - Tencent Holdings (00700) has a short-selling amount of 1.215 billion with a ratio of 11.50% and a deviation of -4.97% [2] Short-Selling Deviation Values - SenseTime-WR (80020) has the highest deviation value at 51.92% [2] - HAPO Pharmaceutical-B (02142) has a short-selling amount of 15,513,500 with a deviation of 37.04% [2] - Lenovo Group-R (80992) has a deviation of 34.69% [2] - Great Wall Motors-R (82333) has a deviation of 30.20% [2]